The FDA has issued an Emergency Use Authorization for Eli Lilly and Co.’s bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.   Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years and older with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, and for whom alternative COVID-19 treatment options are not accessible or clinically ap...